Human medicines European public assessment report (EPAR): Tafamidis Accord, tafamidis, Status: Opinion

Human medicines European public assessment report (EPAR): Ruxolitinib Viatris, ruxolitinib hemifumarate, Status: Opinion

Human medicines European public assessment report (EPAR): Ogsiveo, nirogacestat, Date of authorisation: 14/08/2025, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Riociguat Accord, riociguat, Status: Opinion

Human medicines European public assessment report (EPAR): Pluvicto, lutetium (177Lu) vipivotide tetraxetan, Date of authorisation: 09/12/2022, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Scemblix, asciminib, Date of authorisation: 25/08/2022, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Yondelis, trabectedin, Date of authorisation: 17/09/2007, Revision: 29, Status: Authorised

Questions and answers for biological medicinal products

Human medicines European public assessment report (EPAR): Intrarosa, prasterone, Date of authorisation: 08/01/2018, Revision: 8, Status: Authorised

Paediatric Committee (PDCO): 19-22 May 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 19 May 2026 to 22 May 2026